Sensorion SAS ALSEN
EURONEXT · France · Health Technology
€7.14-0.15 (-2.02%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
MONTPELLIER, France & CAMBRIDGE, Mass., September 23, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company") a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today reported its half-year 2026 results, provided a corporate update and announced the availability of its half-year report.
MONTPELLIER, France & CAMBRIDGE, Mass., September 18, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company"), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces registration and connection details for its SENS-601 Program Day, to be held on September 22, 2026.
Sensorion (ENXTPA:ALSEN) has completed a reverse share split, exchanging every 50 existing shares for 1 new share. The consolidated stock is now trading in Paris under a new ISIN. Recent trading shows Sensorion under pressure, with the share price at €9.70 after declines of about 7% over one day, 19% over the past week and 34% across the last month. This continues a longer pattern of weak total shareholder returns over one, three and five years. This softer momentum sits alongside the new...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.